Overview

An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To determine the effect and safety of Varisolve® 0.125% [0.2%]
Phase:
Phase 2
Details
Lead Sponsor:
Boston Scientific Corporation
BTG International Inc.
Treatments:
Polidocanol